Anastrozole, an aromatase inhibitor, and medroxyprogesterone acetate therapy in premenopausal obese women with endometrial cancer: a report of two cases successfully treated without hysterectomy

Gynecol Oncol. 2004 Sep;94(3):832-4. doi: 10.1016/j.ygyno.2004.06.004.

Abstract

Background: Hormonal therapy for endometrial cancer is occasionally warranted in the premenopausal woman who is interested in maintaining fertility. Combining progesterone with an agent that eliminates the adipose production of estrogen will theoretically be more effective than progesterone alone.

Cases: Two cases of reproductive-aged women with grade 1 endometrial cancer who were treated with medroxyprogesterone acetate and anastrozole daily for 3 and 6 months subsequently reverted to normal endometrium.

Conclusion: Progesterone combined with the elimination of adipose production of estrogen may be an effective therapy in well-differentiated endometrial cancer in the obese premenopausal woman.

MeSH terms

  • Adult
  • Anastrozole
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Aromatase Inhibitors
  • Endometrial Neoplasms / complications
  • Endometrial Neoplasms / drug therapy*
  • Female
  • Humans
  • Medroxyprogesterone Acetate / administration & dosage
  • Nitriles / administration & dosage
  • Obesity / complications*
  • Triazoles / administration & dosage

Substances

  • Aromatase Inhibitors
  • Nitriles
  • Triazoles
  • Anastrozole
  • Medroxyprogesterone Acetate